Buys
Open market- Shares
- Avg price
- Total value
Fairmount Funds Management LLC - Director at Spyre Therapeutics, Inc.
Issuer-level insider activity
- Role
- Director
- Issuer ticker
- SYRE on Nasdaq
- Entity type
- Company
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
Past-year transaction volume for Fairmount Funds Management LLC in Spyre Therapeutics, Inc.
Sells
Open market- Shares
- -4,684,781
- Avg price
- $85.31
- Total value
- -$399,658,667
Net
Past year- Shares
- -4,684,781
- Share %
- -100%
- Total value
- -$399,658,667
Reported holdings for Fairmount Funds Management LLC in Spyre Therapeutics, Inc.
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 406,038
- Estimated value
- $20,480,556
- Report date
- 23 Jun 2026
- Price
- $50.44
- Ownership
- By Peter Harwin
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 406,038
- Estimated value
- $20,480,556
- Report date
- 23 Jun 2026
- Price
- $50.44
- Ownership
- By Peter Harwin
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 406,038
- Estimated value
- $20,480,556
- Report date
- 23 Jun 2026
- Price
- $50.44
- Ownership
- By Peter Harwin
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 406,038
- Estimated value
- $20,480,556
- Report date
- 23 Jun 2026
- Price
- $50.44
- Ownership
- By Peter Harwin
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 406,038
- Estimated value
- $20,480,556
- Report date
- 23 Jun 2026
- Price
- $50.44
- Ownership
- By Tomas Kiselak
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 406,038
- Estimated value
- $20,480,556
- Report date
- 23 Jun 2026
- Price
- $50.44
- Ownership
- By Tomas Kiselak
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 406,038
- Estimated value
- $20,480,556
- Report date
- 23 Jun 2026
- Price
- $50.44
- Ownership
- By Tomas Kiselak
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 406,038
- Estimated value
- $20,480,556
- Report date
- 23 Jun 2026
- Price
- $50.44
- Ownership
- By Tomas Kiselak
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 23 Jun 2026
- Price
- $85.31
- Ownership
- By Fairmount Healthcare Fund II L.P.
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 23 Jun 2026
- Price
- $85.31
- Ownership
- By Fairmount Healthcare Fund II L.P.
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 23 Jun 2026
- Price
- $85.31
- Ownership
- By Fairmount Healthcare Fund II L.P.
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 23 Jun 2026
- Price
- $85.31
- Ownership
- By Fairmount Healthcare Fund II L.P.
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 346,045
- Estimated value
- Report date
- 23 Jun 2026
- Price
- Ownership
- Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 346,045
- Estimated value
- Report date
- 23 Jun 2026
- Price
- Ownership
- Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 346,045
- Estimated value
- Report date
- 23 Jun 2026
- Price
- Ownership
- Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Series A Preferred Stock
- Shares / value
- 346,045
- Estimated value
- Report date
- 23 Jun 2026
- Price
- Ownership
- Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 25,000
- Estimated value
- Report date
- 29 May 2025
- Price
- Ownership
- By Peter Harwin
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 8,026
- Estimated value
- Report date
- 27 May 2026
- Price
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 8,026
- Estimated value
- Report date
- 27 May 2026
- Price
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 8,026
- Estimated value
- Report date
- 27 May 2026
- Price
- Ownership
- By Tomas Kiselak
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 23 Jun 2026
- Price
- Ownership
- Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 23 Jun 2026
- Price
- Ownership
- Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 23 Jun 2026
- Price
- Ownership
- Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Spyre Therapeutics, Inc.
- Security class
- Series B Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 23 Jun 2026
- Price
- Ownership
- Fairmount Healthcare Fund II LP
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Fairmount Funds Management LLC in Spyre Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.